Seguir
Meletios Athanasios  Dimopoulos
Meletios Athanasios Dimopoulos
Dirección de correo verificada de med.uoa.gr
Título
Citado por
Citado por
Año
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
49682014
International uniform response criteria for multiple myeloma
BGM Durie, JL Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, ...
Leukemia 20 (9), 1467-1473, 2006
34412006
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
International Myeloma Working Group
British journal of haematology 121 (5), 749-757, 2003
26142003
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
24802016
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ...
New England Journal of Medicine 359 (9), 906-917, 2008
24562008
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ...
Journal of clinical oncology 33 (26), 2863, 2015
21462015
Hematological findings and complications of COVID‐19
E Terpos, I Ntanasis‐Stathopoulos, I Elalamy, E Kastritis, TN Sergentanis, ...
American journal of hematology 95 (7), 834-847, 2020
21192020
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
M Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, ...
New England Journal of Medicine 357 (21), 2123-2132, 2007
18192007
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors
A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ...
J Clin Oncol 23 (34), 8580-7, 2005
16052005
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ...
New England Journal of Medicine 372 (2), 142-152, 2015
15812015
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ...
New England Journal of Medicine 375 (14), 1319-1331, 2016
15782016
Elotuzumab therapy for relapsed or refractory multiple myeloma
S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ...
New England Journal of Medicine 373 (7), 621-631, 2015
15032015
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
JR Berenson, A Lichtenstein, L Porter, MA Dimopoulos, R Bordoni, ...
New England Journal of Medicine 334 (8), 488-493, 1996
13541996
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
SV Rajkumar, JL Harousseau, B Durie, KC Anderson, M Dimopoulos, ...
Blood, The Journal of the American Society of Hematology 117 (18), 4691-4695, 2011
11252011
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
RG Owen, SP Treon, A Al-Katib, R Fonseca, PR Greipp, ML McMaster, ...
Seminars in oncology 30 (2), 110-115, 2003
11032003
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hájek, ...
Leukemia 23 (2), 215-224, 2009
10362009
Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma
A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, ...
Leukemia 22 (2), 414-423, 2008
10222008
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and …
RA Kyle, BGM Durie, SV Rajkumar, O Landgren, J Bladé, G Merlini, ...
Leukemia 24 (6), 1121-1127, 2010
10162010
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label …
J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ...
The lancet oncology 14 (11), 1055-1066, 2013
10132013
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
10072012
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20